Brand: iMatrix™ by Matrixome®
Purchase product: USA Store
|Product Code||Pack Size||Price in
|Prices in UK, Europe,
Middle East & Africa
|NP892-021||175 μg × 6 tubes||USD $ 518.00||GBP £ 464.51||EUR € 527.23|
Prices do not include shipping and handling charges/
An alternative iMatrix-511 that is xeno-free, recombinant Laminin-511 E8 Fragment expressed in silkworm for promoting adherence and culture of human iPS cells. iMatrix-511 SILK is similar in performance, but lower in cost relative to NP892-011.
iMatrix-511 SILK is a highly purified and refined laminin-511 E8 fragments, produced in Silkworms.
iMatrix-511 SILK features make it an ideal matrix for pluripotent stem cell culture:
Laminin is localized to the basement membrane and plays a key role in cell adhesion and proliferation. Laminin-511 (α5, β1 laminin) binds to integrin α6β1 to promote cell signaling. Laminin-511 provides an ideal matrix for the proliferation of a wide variety of cell types including stem and iPS cells.
iMatrix-511 SILK is functionally equivalent to iMatrix-511 (Cat. No. NP892-011). The only difference is the expression system used for bioproduction. The iMatrix-511 SILK product is produced in recombinant silkworm cocoon, while iMatrix-511 is produced in CHO-S cells. Both are E8 fragments that have been purified using the same processes.
Product Name: iMatrix-511 SILK Stem Cell Culture Substrate
Catalog Number: NP892-021
Size: 6 × 175 µg
Molecular Weight: 150 kDa
Purity: > 95 % pure
Formulation: Purified Laminin-511 E8 proteolytic fragment
Storage and Stability: Store at 4 °C and protect from light exposure. Stable for 2 years from the manufacturing date.
Concentration: 500 µg/mL
Quality Control: Integrin binding Kd < 10 nM
Notice To Purchaser: REPROCELL is a licensed distributor of Matrixome cell culture substrates to the global market.
Recommended Usage: iMatrix-511-SILK is suitable for use as a substrate for the culture of various cell types, including ES/iPS cells.
Manufacturer: Matrixome Corporation (Japan)
Stem Cells / 13 September 2021
Clinical Capabilities / 9 September 2021
15 September 2021
2 September 2021
18 August 2021
© 2021 REPROCELL Inc. All rights reserved.